iVoice Subsidiary's Acid+All(TM) Brings Valentine's Cheer to San Francisco.

MATAWAN, N.J. -- Thomas Pharmaceuticals Ltd. ("Thomas Pharmaceuticals"), a wholly owned subsidiary of iVoice, Inc. (OTCBB:IVOI), announced today that is set to toast San Francisco with an Acid+All[TM] Valentine's. Those on the go - on the way to work, to meet friends, colleagues, that special Valentine's date - will be greeted in San Francisco on Valentine's Day, February 14th, by the signature seersucker-dressed Acid+All Ambassadors offering a sample of Acid+All and along with three clever Valentine's postcards inspiring recipients to "Follow your Heart - Not your Heartburn." The sampling program will increase consumer awareness of the product and support retailers such as Long's and Walgreens in the key San Francisco market.

"We're excited to be back on the street to support retailers and to continue building relationships with our consumers. There are particular nuances to effectively reaching the special needs of today's baby boomer generation. Doing so is an area of expertise for Thomas Pharmaceuticals Ltd. - enabling us to build trust with key retailers and consumers early on," said Tom Thomas, Founder and President of Thomas Pharmaceuticals Ltd. "We excel at bringing to market niche brands that help people look better and feel better. These genuine, authentic and simple brands bring strong returns to retailers and shareholders."

Introduced in June, Acid+All[TM] has achieved breakthrough distribution on more than 20,000 chain drug stores nationwide. Thomas Pharmaceuticals Ltd.'s launch has been described by industry professionals as one of the most imaginative, pragmatic and uniquely successful campaigns in the last 40 years. Acid+All was named one of the Top 10 New Products by the Editors of Drug Store News, and described as on-target for today's niche consumer by Supermarket News, Nicholas Halls Report and The Wall Street Journal. Tom Thomas and Thomas Pharmaceuticals Ltd. are featured, along with Kodak, Sphere and Van Sneakers in a documentary film on "Smart Marketers" produced by Thompson Financial for distribution in over 1,100 university classrooms this Fall.

Acid+All[TM], the calcium enriched, spearmint-flavored, sugar free tablets that soothe heartburn, acid indigestion and gas is available at independent pharmacies, major drug chains and online retailers or by calling toll-free at 1-888-922-1959. Acid+All[TM] is available in a sleek, 32-count pillbox. For more information about Acid+All[TM] go to www.acidall.com.

About Thomas Pharmaceuticals

Thomas Pharmaceuticals Ltd., based in New York, N.Y., develops and markets over the counter non-prescription healthcare products. The company focuses on high-end, branded consumables. Its first product, Acid+All[TM], is a calcium-enriched, sugar free, anti-gas antacid. On August 9, 2006, iVoice, Inc. entered into a Stock Purchase Agreement dated August 7, 2006 by and among Thomas Pharmaceuticals Ltd.,Thomas Pharmaceutical Acquisition Corp. ("Thomas Acquisition") and iVoice, Inc. whereby Thomas Acquisition has agreed to purchase all of the outstanding securities presently held by iVoice. iVoice has extended this Stock Purchase Agreement. Thomas Acquisition is substantially controlled by the original founders and management of Thomas Pharmaceuticals.

About iVoice, Inc:

iVoice has determined that the best way to create shareholder value, separate and apart from the operating performance of iVoice, is to implement new business opportunities by distributing shares of spin-offs to the company's shareholders. The common stock distributions are part of a broader strategy relating to the transition of iVoice into a company focused on the development and licensing of proprietary technologies. We also continue to search for potential merger candidates with or without compatible technology and products, which management feels may make financing more appealing to potential investors.

Certain information included in this press release, may contain forward-looking statements about our current and expected performance trends, growth plans, business goals and other matters. These statements may be contained in our filings with the Securities and Exchange Commission, in our press releases, in other written communications, and in oral statements made by or with the approval of one of our authorized officers. Information set forth in this press release contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act of 1995 (the "Act") provides certain "safe harbor" provisions for forward-looking statements. The reader is cautioned that such forward-looking statements are based on information available at the time and/or management's good faith belief with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Forward-looking statements speak only as of the date the statement was made. We assume no obligation to update forward-looking information to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information. Forward-looking statements are typically identified by the use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "should," "will," and similar words, although some forward-looking statements are expressed differently. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.

For more information on iVoice, please visit http://www.ivoice.com or http://www.thomaspharmaceuticals.com/.